While challenges remain, especially when it comes to overcoming stigma, calling out antiquated HIV criminalization laws and HIV funding at home and abroad, the latest breakthrough in HIV prevention could transform how individuals manage their risk.
For many people at high risk of HIV, the current prevention options—like daily oral pre-exposure prophylaxis (PrEP)—are effective but can be challenging to maintain.
Adherence to daily medications, while life-saving, can be difficult for a variety of reasons, from forgetfulness to stigma surrounding HIV and PrEP.
In response to these barriers, the potential of a twice-yearly injectable PrEP option offers hope for a more manageable and discreet approach to prevention.
Gilead’s lenacapavir injection, which is under priority review by the FDA, would provide a groundbreaking alternative for individuals at high risk of HIV exposure.
He emphasized that expanding access to PrEP is critical for achieving a world where new HIV cases are rare, not inevitable.
This is why lenacapavir’s potential to offer an injectable option—one that is easier to adhere to—could revolutionize HIV prevention efforts. »
